The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients

Clinical and Experimental Nephrology

Volumn 19, Issue 3, 2015, Pages 443-449

  Bayram, Dilara ^a   Tugrul Sezer M ^a   İnal, Salih ^a   Altuntaş, Atila ^a   Kıdır, Veysel ^a   Orhan, Hikmet ^a  

^a SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

Allopurinol; Chronic kidney disease; Endothelial dysfunction; Hyperuricemia; Metabolic acidosis

Indexed keywords

ALLOPURINOL; BICARBONATE; C REACTIVE PROTEIN; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID; ANTIGOUT AGENT;

ADULT; AGE; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ENDOTHELIUM; FEMALE; FLOW MEASUREMENT; HUMAN; MALE; METABOLIC ACIDOSIS; PROSPECTIVE STUDY; PROTEINURIA; SEX DIFFERENCE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; VENOUS BLOOD; ACIDOSIS; AGED; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG EFFECTS; HYPERURICEMIA; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; URINE; VASODILATATION;

ACIDOSIS; ADULT; AGED; ALLOPURINOL; BICARBONATES; CREATININE; ENDOTHELIUM; FEMALE; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; URIC ACID; VASODILATION;

EID: 84931010118     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-014-1012-z     Document Type: Article

References (25)

1. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.
2. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Clev Clin J Med. 2008;75:13–6.
3. Saito T, Mochizuki T, Uchida K, Tsuchiya K, Nitta K. Metabolic syndrome and risk of progression of chronic kidney disease: a single-center cohort study in Japan. Heart Vessels. 2013;28:323–9.
4. Sundström J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28–33.
5. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50:239–47.
6. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811–21.
7. Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol. 2011;33:298–304.
8. Kawashima M, Wada K, Ohta H, Terawaki H, Aizawa Y. Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol. 2011;12:1–7.
9. Miyaoka T, Mochizuki T, Takei T, Tsuchiya K, Nitta K. Serum uric acid levels and long-term outcomes in chronic kidney disease. Heart Vessels. 2013. doi:10.1007/s00380-013-0396-0.
10. Pai BH, Swarnalatha G, Ram R, Dakshinamurty KV. Allopurinol for prevention of progression of kidney disease with hyperuricemia. Indian J Nephrol. 2013;23:280–6.
11. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39:1227–33.
12. Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, et al. Uric acid and inflammatory markers. Eur J Heart. 2006;27:1174–81.
13. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739–42.
14. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508–16.
15. Gustafsson D, Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013;14:164.
16. Sincer I, Kurtoglu E, Calıskan M, Akkaya E, Vuruskan E, Küçükosmanoglu M, et al. Significant correlation between uric acid levels and flow-mediated dilatation in patients with masked hypertension. Clin Exp Hypertens. 20 Feb 2014 [Epub ahead of print]. doi:10.3109/10641963.2013.827694.
17. Williams B, Hattersley J, Layward E, Walls J. Metabolic acidosis and skeletal muscle adaptation to low-protein diets in chronic uremia. Kidney Int. 1991;40:779–86.
18. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20:2075–84.
19. Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, et al. Amelioration of metabolic acidosis in individuals with low GFR reduces kidney endothelin production, reduces kidney injury, and better preserves GFR. Kidney Int. 2010;77:617–23.
20. Gao H, Lew SQ, Bosch JP. Moderate metabolic acidosis and its effects on serum parameters in hemodialysis patients. Nephron. 2000;86:135–8.
21. Moviat M, Terpstra AM, Ruitenbeek W, Kluijtmans LA, Pickkers P, van der Hoeven JG. Contribution of various metabolites to the unmeasured anions in critically ill patients with metabolic acidosis. Crit Care Med. 2008;36:752–8.
22. Forni LG, McKinnon W, Lord GA, Treacher DF, Peron JM, Hilton PJ. Circulating anions usually associated with the Krebs cycle in patients with metabolic acidosis. Crit Care. 2005;9:R591–5.
23. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981–3.
24. Paisansinsup T, Breitenstein MK, Schousboe JT. Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol. J Clin Rheumatol. 2013;19:180–6.
25. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646–50.